Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Chinese Journal of Endocrine Surgery ; (6): 516-519, 2022.
Artículo en Chino | WPRIM | ID: wpr-954631

RESUMEN

Although adding platinum to taxane- and anthracycline-based neoadjuvant chemotherapy regimens for triple-negative breast cancer (TNBC) patients can significantly improve the pathological complete response (pCR) rate and long-term survival, it is associated with higher treatment-related adverse events (AEs) . Current researches focus on the response predictors to select patients who may benefit from platinum-based chemotherapy. Homologous recombination deficiency (HRD) can identify patients who truly need platinum drugs, that is, those with BRCA wild-type but HRD tumors. Results suggest that anthracycline-based chemotherapy is sufficient for BRCA mutation carriers and that non-HRD carriers will not benefit from the added carboplatin.

2.
Journal of Breast Cancer ; : 47-58, 2020.
Artículo en Inglés | WPRIM | ID: wpr-811197

RESUMEN

PURPOSE: Tau is a microtubule-associated protein that can be found in both normal and abnormal breast cells. Whether the expression of Tau protein can predict the response to neoadjuvant chemotherapy (NACT) is still unclear. In this study, we assessed the role of Tau protein expression in predicting a pathological complete response (pCR) to NACT for different subtypes of breast cancer.METHODS: Four hundred and sixty-eight eligible patients were retrospectively recruited in our study. The relationship between clinicopathologic factors, including Tau protein expression, and pCR in different subtypes was evaluated using logistic regression analysis. Correlation between Tau and disease-free survival (DFS) and overall survival (OS) was performed using Kaplan–Meier analysis.RESULTS: The expression of Tau protein was negatively correlated with pCR, especially in triple-negative breast cancer (TNBC). No significant difference was observed in the luminal human epidermal growth factor receptor-2 (HER2)-negative subtype and HER2-positive subtype. Patients with pCR were associated with better DFS and OS (p < 0.05). However, Tau protein expression had no association with either DFS or OS (p > 0.05).CONCLUSION: Tau protein expression can predict pCR before NACT in TNBC, but there was no correlation between Tau expression and DFS or OS.


Asunto(s)
Humanos , Neoplasias de la Mama , Mama , Supervivencia sin Enfermedad , Quimioterapia , Factor de Crecimiento Epidérmico , Modelos Logísticos , Terapia Neoadyuvante , Fenobarbital , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos , Proteínas tau , Neoplasias de la Mama Triple Negativas
3.
Journal of Breast Cancer ; : 230-231, 2020.
Artículo | WPRIM | ID: wpr-835598

RESUMEN

This corrects the article “Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer” in volume 23 on page 47.This article was initially published on the Journal of Breast Cancer with a misspelled the abbreviation in figure 3. The abbreviation ‘HP’ should be corrected as ‘HR’.

4.
Chongqing Medicine ; (36): 770-772, 2018.
Artículo en Chino | WPRIM | ID: wpr-691867

RESUMEN

Objective To explore the correlation between the detection rate of diffusion weighted imaging(DWI) in diagnosis prostate cancer and the Gleason score.Methods Ninety-one cases of intact pathological data and clinically suspected prostate cancer were collected.All cases were undertaken the routine sequence (TIWI/T2WI) and DWI (value b=600 s/mm2) examination.The cases of pathologically diagnosed prostate cancer were performed the Gleason score.Results Among 91 cases,44 cases were benign prostatic hyperplasia(BPH) and 47 cases were prostate carcinoma(PCa).The ADC values in the BPH group and PCa group were (1.250±0.263)× 10-3mm2/s and (0.955±0.191)× 10-3mm2/s.According to Gleason score,the PCa group was re-divided into three sub-groups:high differentiation,middle differentiation and low differentiation,the apparent diffusion coefficient(ADC) values were (1.158±0.173)× 10-3mm2/s,(1.050±0.192)× 10-3mm2/s and (0.891±0.241) × 10-3 mm2/s respectively.Their diagnostic accuracy rates for diagnosing PCa were 63.6%,78.3% and 84.6% respectively.The ADC value of different pathological groups in PCa with Gleason score is negatively correlated with the Gleason score.The accuracy rate of DWI in diagnosis of PEa is positively correlated with the Gleason score.Conclusion The lower prostate cancer differentiation,the higher Gleason score and the higher accuracy of DWI in diagnosing PCa.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA